A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

By sjmartinez • April 8, 2024

Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Trukhin D, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Kohlmann M, Lowery C, Mann H, Peters S, Mok TS, Johnson ML. A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study. Clin Lung Cancer. 2024 Mar 15:S1525-7304(24)00038-X. doi: 10.1016/j.cllc.2024.03.003. Epub ahead of print. PMID: 38584069.

Tags: Clinical Trial, Cytotoxic T-lymphocyte-associated antigen 4, Hematology/Oncology, immune checkpoint inhibitor, immunotherapy, Programmed cell death ligand-1, Publications

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study

Kim YJ, Merle P, Finn RS, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Pinter M, Babajanyan S, Twumasi-Ankrah P, Ghadessi[...]

Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance

Markosian C, Buckley CW, Chai-Ho W, Schiller GJ. Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance. Leuk[...]

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer

Su Y, Liu C, Lu X, Chuang HY, Li G, Shao S, Kong Y, Lee JW, Ng RH, Wong S, Robert L, Warden C, Liu[...]